Background. Organ transplant recipients who are seropositive for cytomegalovirus (CMV)
and who are treated with antilymphocyte antibody (ALA) therapy have a high rate of …

Cytomegalovirus (CMV) continues to be a cause of substantial morbidity and death after
solid-organ transplantation. There are 3 major consequences of CMV infection: CMV …

Ganciclovir is a nucleoside analogue which is used to treat and prevent cytomegalovirus
(CMV) infection. Most recent clinical studies of ganciclovir in transplant recipients have …

Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ
transplantation, with a significant impact on transplant outcomes. Prevention strategies …

INTRODUCTION: Cytomegalovirus (CMV) infection after solid organ transplantation is one
of the most common viral infections, causing significant morbidity and mortality if not treated …

CMV infection is a major cause of morbidity in patients receiving solid organ transplants.
CMV is widely distributed in the general population with seroprevalence ranging from 30 to …

Background. Ganciclovir‐resistant (GCV‐R) cytomegalovirus (CMV) is now being reported
with increasing frequency in solid organ transplant recipients. Objective. To describe the …

Background. About one-quarter of renal transplant patients will suffer from symptomatic
cytomegalovirus (CMV) disease if no preventive therapeutic measures are taken. In this …

Quantitative polymerase chain reaction (QPCR) for cytomegalovirus (CMV) is emerging as
the preferred screening method for detection of CMV viremia in patients following allogeneic …

The Canadian Society of Transplantation sponsored a Cytomegalovirus (CMV) Consensus
Working Group that met on March 19, 2003. The objectives of this group were to determine …